Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia (Q24248048)

27 June 2017

1 reference

title

Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia (English)

0 references

Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia (English)

1 reference

27 June 2017

5

0 references

Mical Paul

1

M Paul

1 reference

27 June 2017

4

0 references

Leonard Leibovici

4

L Leibovici

1 reference

Simona Grozinsky-Glasberg

27 June 2017

3

Simona Grozinsky-Glasberg

0 references

Agata Schlesinger

2

Agata Schlesinger

0 references

Karla Soares-Weiser

2

K Soares-Weiser

1 reference

27 June 2017

S Grozinsky

3

1 reference

27 June 2017

language of work or name

English

0 references

publication date

21 July 2003

0 references

1 January 2003

1 reference

Cochrane Database of Systematic Reviews

27 June 2017

2002

0 references

published in

1 reference

27 June 2017

issue

3

1 reference

27 June 2017

2

0 references

page(s)

CD003038

1 reference

Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Treatment of neutropenic infection: a randomized trial comparing latamoxef (moxalactam) with cephradine plus tobramycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Comparison of cefepime versus ceftriaxone-amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Imipenem versus gentamicin combined with either cefuroxime or cephalothin as initial therapy for febrile neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Early identification of neutropenic patients at risk of grampositive bacteraemia and the impact of empirical administration of vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Comparison of imipenem versus cefuroxime plus tobramycin as empirical therapy for febrile granulocytopenic patients and efficacy of vancomycin and aztreonam in case of failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

A randomised trial of empirical antibiotic therapy in febrile neutropenic patients with hematological disorders: ceftazidime versus azlocillin plus amikacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Ceftazidime versus ceftazidime plus tobramycin in febrile neutropenic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Ceftazidime monotherapy is as effective as ceftazidime combined with gentamicin in the treatment of febrile neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Ceftazidime as a single agent in the management of children with fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Imipenem/cilastatin versus piperacillin plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with haematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Amikacin plus piperacillin versus ceftazidime as initial therapy in granulocytopenic patients with presumed bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Ceftriaxone vs. azlocillin and netilmicin in the treatment of febrile neutropenic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

A prospective randomized study comparing the efficacy of Timentin alone or in combination with amikacin in the treatment of febrile neutropenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Randomized Comparison of Ceftriaxone versus Cefriaxone plus Amikacin for the Empirical Treatment of Infections in Patients with Altered Host Defense: Microbiological and Clinical Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Imipenem-antibiotic monotherapy in juvenile cancer patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Comparative study of ceftriaxone monotherapy versus a combination regimen of cefuroxime plus gentamicin for treatment of serious bacterial infections: the efficacy, safety and effect on fecal flora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Prospective comparative trial of short course (four day) and continuous tobramycin in combination with cefoperazone or mezlocillin in febrile, granulocytopenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Ceftazidime compared to tobramycin and ticarcillin in immunocompromised haematological patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Infections in cancer patients.Results with gentamicin sulfate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Single versus combination intravenous antibiotic therapy for people with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Can

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Aspergillosis case-fatality rate: systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients: analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Treatment of septicaemia in immunocompromised patients with ceftazidime or with tobramycin and cefuroxime, with special reference to renal effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Initial empiric therapy for fever in neutropenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Antibiotic therapy for the febrile granulocytopenic cancer patient: combination therapy vs. monotherapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Synergistic combinations of antibiotics in gram-negative bacillary infections.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Gram-negative bacterial infections: a look at the past, a view of the present, and a glance at the future

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Synergism between amikacin and cefazolin against Klebsiella: in vitro studies and effect on the bactericidal activity of serum

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

A randomized prospective study of imipenem-cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Beta-lactam antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Re

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Empiric therapy of infections in hematologic malignancies: a prospective, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Comparative efficacy and toxicity of moxalactam and the combination of nafcillin and tobramycin in febrile granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003038

7 January 2021

10.1002/14651858.CD003038

Identifiers

DOI

1 reference

27 June 2017

1 reference